What is Neuronostics?
Neuronostics operates at the intersection of advanced mathematics and clinical neurology, focusing specifically on the optimization of epilepsy diagnosis. The company's flagship innovation, BioEP, represents a significant departure from traditional EEG interpretation methods. By utilizing sophisticated digital analysis to extract reliable biomarkers from EEG data, Neuronostics addresses the inherent limitations of conventional diagnostic workflows. This technological approach not only enhances the accuracy of epilepsy identification but also streamlines the diagnostic process for healthcare providers. Through strategic collaborations with NHS Trusts and academic institutions, the company is actively bridging the gap between theoretical mathematical modeling and practical, bedside clinical application, thereby setting a new standard for neurological care.
How much funding has Neuronostics raised?
Neuronostics has raised a total of $2.7M across 1 funding round:
Angel/Seed
$2.7M
Angel/Seed (2024): $2.7M with participation from QantX, Ascension Life Science, and Empirical Ventures
Key Investors in Neuronostics
QantX
QantX is a venture capital firm focused on supporting early-stage companies with high-growth potential, particularly those developing disruptive technologies in the science and engineering sectors.
Ascension Life Science
Ascension Life Science is a prominent distributor of scientific and medical supplies with over ten years of experience, specializing in providing innovative solutions for diagnostic applications.
Empirical Ventures
Empirical Ventures is an investment firm that provides strategic capital to innovative startups, focusing on companies that leverage data and technology to solve complex industry problems.
What's next for Neuronostics?
Looking ahead, the strategic deployment of this capital will likely focus on the commercial expansion of the BioEP platform and the deepening of clinical validation studies. As the company transitions from development to broader market adoption, the focus will shift toward integrating these digital biomarkers into standard clinical pathways across diverse healthcare settings. The support from key investors provides the necessary runway to navigate regulatory milestones and scale the infrastructure required to support a growing user base. By maintaining its commitment to rigorous scientific inquiry and collaborative partnerships, Neuronostics is poised to influence the future of neurological health, potentially reducing the time-to-diagnosis and improving long-term outcomes for patients suffering from epilepsy.
See full Neuronostics company page
